- Conditions
- Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
- Interventions
- TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, TTI-621 + T-Vec, TTI-621 + radiation
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 7
- States / cities
- Duarte, California • New York, New York • Portland, Oregon + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Pembrolizumab, Pevonedistat
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 31
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more
- Conditions
- Bladder Cancer
- Interventions
- Intravenous MK-3475/ Intravesical BCG
- Drug
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 3
- States / cities
- Springfield, Illinois • Detroit, Michigan
- Conditions
- Pancreatic Cancer
- Interventions
- Pembrolizumab, Neoadjuvant Chemoradiation
- Drug · Radiation
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Hartford, Connecticut • Miami, Florida + 3 more
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- Pembrolizumab + sEphB4-HSA
- Drug
- Lead sponsor
- Vasgene Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
- Interventions
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Genelux Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
- Conditions
- Solid Tumors
- Interventions
- INCB001158, Epacadostat, Pembrolizumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Chicago, Illinois
- Conditions
- Advanced/Metastatic NSCLC
- Interventions
- Immunotherapy - PD-1 Blocker
- Drug
- Lead sponsor
- Liza Villaruz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, Refractory Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Ependymoma, Refractory Medulloblastoma
- Interventions
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-enhanced MR Perfusion, Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging, Magnetic Resonance Spectroscopic Imaging, Pembrolizumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Oligometastatic Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pembrolizumab, Lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more
- Conditions
- Acute Myeloid Leukemia, in Relapse
- Interventions
- pembrolizumab,
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Chapel Hill, North Carolina
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
- Interventions
- PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6
- Drug
- Lead sponsor
- Ikena Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more
- Conditions
- Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Dinaciclib, Pembrolizumab
- Drug
- Lead sponsor
- Jo Chien
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- GastroEsophageal Cancer, Gastric Cancer
- Interventions
- Neratinib, Trastuzumab, Oxaliplatin, 5-Fluorouracil + leucovorin, Pembrolizumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Metastatic Melanoma
- Interventions
- Cabozantinib, Pembrolizumab
- Drug
- Lead sponsor
- John Rieth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- Lenvatinib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
- Device · Drug
- Lead sponsor
- NovoCure GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Fullerton, California + 33 more
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
- Interventions
- Nivolumab, Atezolizumab, Radiation & immunotherapy, Pembrolizumab
- Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cervix Cancer, Cervical Cancer
- Interventions
- Pembrolizumab, Lenvatinib
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
- Interventions
- Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine, 5-Fluorouracil, Docetaxel, Nutrition questionnaires (optional), stool and saliva samples (optional)
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Enzalutamide, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
- Conditions
- Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma, Advanced or Metastatic Solid Tumors
- Interventions
- Cavrotolimod, Pembrolizumab, Cemiplimab
- Drug · Biological
- Lead sponsor
- Exicure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 21 more